Nitric oxide (NO) deficiency induced by the NO synthase (NOS) inhibitor N G -nitro-L-arginine-methyl ester (L-NAME) resulted in hypertension. L-citrulline (CIT) can be converted to L-arginine to generate NO. We examined whether maternal CIT supplementation can prevent L-NAME-induced programmed hypertension. Pregnant Sprague-Dawley rats were assigned to four groups: control, L-NAME, control + citrulline (CIT), and L-NAME + citrulline (L-NAME+CIT). Pregnant rats received L-NAME administration at 60 mg/kg/day subcutaneously during pregnancy alone or with additional 0.25% L-citrulline solution in drinking water during the whole period of pregnancy and lactation. Male offspring were sacrificed at 12 wk of age. L-NAME exposure during pregnancy induces hypertension in the 12-wk-old offspring. Maternal CIT therapy prevented L-NAMEinduced programmed hypertension, which was associated with a decreased asymmetric dimethylarginine (ADMA) concentration and an increased L-arginine-to-ADMA ratio in the kidney, increased urinary cGMP levels, and decreased renal protein levels of type 3 sodium hydrogen exchanger (NHE3). Together, our data suggest that the beneficial effects of CIT supplementation are attributed to its ability to increase NO level in the kidney and inhibition of NHE3 expression. Our results suggest that supplementing CIT in pregnant women with NO deficiency can improve fetal development and prevent programmed hypertension.
INTRODUCTION
Nitric oxide (NO) regulates feto-placental vascular reactivity and placental blood flow, while NO deficiency leads to deranged hemodynamic adaptations of pregnancy [1] [2] [3] . The developing kidney is particularly susceptible to NO deficiency. In NO-depleted rats, altered pro-and antioxidative gene expression in the kidney causes a disturbed redox balance, leading to hypertension [4] . Accumulating evidence indicates that decreased NO bioavailability and increased reactive oxygen species (ROS) production in the kidney are present in various experimental models of hypertension [5] [6] [7] . Environmental insults during maternal and perinatal phases can elicit epigenetic regulation in genes for nephrogenesis and reset physiological responses to develop hypertension in adulthood, namely, developmental programming [8] . It has been shown that chronic inhibition of the NO synthase (NOS) with N G -nitro-L-arginine-methyl ester (L-NAME) results in hypertension in pregnant rodents [2, 9] . Given the crucial role of NO in pregnancy, it is clinically important to elucidate the effects of L-NAME-induced NO deficiency in pregnant rats on the programmed hypertension in adult offspring, with a focus on the kidney.
Another inhibitor of NOS is asymmetric dimethylarginine (ADMA). We and others have demonstrated that ADMA is involved in the development of hypertension [10] [11] [12] [13] . Free ADMA levels are controlled by two counterbalancing pathways: type I protein arginine methyltransferase (PRMT) and dimethylarginine dimethyl-aminohydrolase (DDAH). PRMT-1 is the major type I PRMT enzyme responsible for ADMA synthesis, whereas DDAH isoform-1 (DDAH-1) and DDAH-2 are responsible for ADMA breakdown [12] . We previously reported that an impaired ADMA-NO pathway and low nephron number are associated with programmed hypertension in both maternal caloric restriction and streptozotocin-induced diabetic models [14, 15] . Oxidative stress, epigenetic regulation, alterations of renin-angiotensin system (RAS) and sodium transporters, and a reduction in nephron numbers have been proposed to interpret programming of hypertension [8] .
L-citrulline (CIT) can be converted to L-arginine (ARG) by argininosuccinate synthase (ASS) and argininosuccinate synthase lyase (ASL) in many tissues, and it can bypass hepatic metabolism; therefore, CIT supplementation becomes an alternative to augment NO [16] . This notion is supported by us and others showing that maternal CIT supplementation increased NO bioavailability to prevent the programming of hypertension [7, 14, 17, 18] . The study was therefore designed to examine whether maternal CIT supplementation can prevent programmed hypertension caused by maternal L-NAMEinduced NO deficiency and to explore the underlying mechanisms.
MATERIALS AND METHODS

Animals and Experimental Design
This experiment was approved and performed under the Guidelines for Animal Experiments of Chang Gung Memorial Hospital and Chang Gung University. Virgin Sprague-Dawley (SD) rats (10 wk old) were obtained (BioLASCO Taiwan Co., Ltd, Taipei, Taiwan) and maintained in a facility accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International. Male rats were caged with individual females until mating was confirmed by observation of a vaginal plug.
Pregnant rats were assigned to four groups (n ¼ 3/group): control, L-NAME, control þ citrulline (CIT), and L-NAME þ citrulline (L-NAMEþCIT). Pregnant rats (n ¼ 6) received L-NAME administration at 60 mg/kg/day by a subcutaneous osmotic pump (Alza Corporation, Palo Alto, CA) during the whole period of pregnancy [9] . Pregnant rats (n ¼ 6) receiving continuous infusion of iso-osmotic saline were used as controls. Surgery for subcutaneous implantation of an osmotic pump on the dorsum, caudal to the scapulae site of the rat, was performed after i.p. injection of xylazine (10 mg/kg) and ketamine (100 mg/kg). The fur was shaved around the surgical site and treated with a betadine/ethanol mixture (1:1) three times. Ophthalmic ointment was applied to both eyes after induction of anesthesia. Body temperature was maintained by use of a water-circulating heating pad. An incision 1.5 times the diameter of the pump perpendicular to the pump's long axis was made. The subcutaneous tissue was spread to create a pocket for the pump. A filled pump was inserted into the pocket. Wound closure was with 3-0 prolene for skin closure. Skin sutures were removed 7-10 days after surgery. All rats were closely monitored during and for 1 h after recovery from general anesthesia and surgery. Rats were returned to normal individual cages and were then monitored every day. Halves of the L-NAME-treated rats (n ¼ 3) or control rats (n ¼ 3) received 0.25% L-citrulline (Sigma, St. Louis, MO) solution dissolved in drinking water during the entire pregnancy and lactation period (i.e., a total of 6 wk), thus covering the entire nephrogenesis period. The dose of L-citrulline used here was based on our previous study conducted in rats [14] . After birth, the subjects came from litters of eight pups to standardize the received quantity of milk and maternal pup care. Each litter was left with the mother until weaning; pups were not weighed at birth to prevent maternal rejection. After weaning, only male offspring (n ¼ 10/group) were selected for further study. From each litter, between three and five pups were finally tested per litter.
Blood pressure (BP) was measured in conscious rats by an indirect tail-cuff method (BP-2000; Visitech Systems, Inc., Apex, NC) [14] . For each rat, five cycles were recorded at each time point. The average of values from three stable measurements was taken. Male offspring were euthanized by an i.p. overdose of pentobarbital at 12 wk of age. The midline of the abdomen was opened, and the intestines were displaced laterally to allow visualization of the aorta. The aorta was dissected from the adjacent vena cava, connective tissue, and fat. The aorta was cannulated with a 20-to 23-gauge butterfly, heparinized blood samples were collected, the vena cava was cut, and PBS was perfused until the kidneys were blanched. Perfused kidneys were harvested, decapsulated, divided into cortex and medulla, flash frozen in liquid nitrogen, and stored at À808C for further analysis. Twenty-four-hour urine was collected in a metabolic cage (Nalgene; Nalge Nunc International, Rochester, NY) prior to euthanization for the determination of urinary excretion of cyclic guanosine monophosphate (cGMP) as a marker of NO production. Urinary cGMP levels were measured using a kit from Cayman Chemicals (Ann Arbor, MI). DDAH activity performed was in kidney homogenates and measured by a colorimetric assay measuring the rate of citrulline production, as we described previously [19] . The DDAH activity was represented as micromole citrulline formation per gram protein per minute at 378C. Since a limited quantity of kidney sample was available in each rat and a large quantity of sample was needed in some experiments, only half the rats in each group (n ¼ 5-6/group) were used for each measure.
Detection of L-Arginine, L-Citrulline, and Dimethylarginine by High-Performance Liquid Chromatography
Plasma L-arginine, L-citrulline, ADMA, and symmetric dimethylarginine (SDMA, a stereoisomer of ADMA) levels were measured using highperformance liquid chromatography (HP series 1100; Agilent Technologies, Inc., Santa Clara, CA) with the o-phthaldialdehyde/3-mercaptopropionic acid derivatization reagent as we described previously [11] . Standards contained concentrations of L-arginine, L-citrulline, ADMA, and SDMA in the range of 1-100, 1-100, 0.5-5, and 0.5-5 lM, respectively. The recovery rate was 90%-105%.
Quantitative Real-Time PCR RNA was extracted using TRIzol reagent treated with DNase I (Ambion, Austin, TX) to remove DNA contamination and reverse transcribed with random primers (Invitrogen, Carlsbad, CA). Control real-time reactions were performed by omitting the real-time enzyme. RNA concentration and quality were checked by control of optical density at 260 and 280 nm. The cDNA product was synthesized using MMLV Reverse Transcriptase (Invitrogen). Two-step quantitative real-time PCR was conducted using the QuantiTect SYBR Green PCR Kit (Qiagen, Valencia, CA) and the iCycler iQ Multi-Color Real-Time PCR Detection System (Bio-Rad, Hercules, CA). Components of the RAS were analyzed, including renin (Ren), prorenin receptor (Atp6ap2), angiotensinogen (Agt), angiotensin converting enzyme (Ace), Ace2, angiotensin II type 1 (Agtr1a) and type 2 (Agtr1b) receptor, and angiotensin (1-7) Mas receptor (Mas1). Four sodium transporters were analyzed in this study, including Na-K-2Cl cotransporter (Slc12a1), type 3 sodium hydrogen exchanger (Slc9a3), Na þ /Cl À cotransporter (Slc12a3), and Na þ /K þ ATPase a1 subunit (Atp1a1). We used 18S rRNA (Rn18s) as a reference. Primers were designed using GeneTool Software (BioTools, Edmonton, AB, Canada). The primer sequences are provided in Supplemental Table S1 (Supplemental Data are available online at www.biolreprod.org). Primer efficiency between 1.8 and 2.2 was acceptable. All samples were run in duplicate. To quantify the relative gene expression, the comparative threshold cycle (C T ) method was employed. For each sample, the average C T value was subtracted from the corresponding average r18S value, calculating the DC T . The DDC T value was calculated by subtracting the average control DC T value from the average experimental DC T . The fold increase of the experimental sample relative to the control was calculated using the formula 2 ÀDDCT .
Western Blot
Western blot analysis was performed as we described previously [11] . A list of antibodies used for Western blotting is given in Supplemental Table S2 . Bands of interest were visualized using ECL reagents (PerkinElmer, Waltham, MA) and quantified by densitometry (Quantity One Analysis software; BioRad) as integrated optical density (IOD) after subtraction of background. The IOD was factored for Ponceau red staining to correct for any variations in total protein loading. The protein abundance was represented as IOD/PonS.
Statistical Analysis
Data are given as mean 6 SEM. For most parameters, statistical analysis was done using one-way ANOVA with Tukey post hoc test for multiple comparisons. BP was analyzed by two-way repeated-measures ANOVA and Tukey post hoc test. A P-value of ,0.05 was considered statistically significant. All analyses were performed using the Statistical Package for the Social Sciences software (SPSS, Chicago, IL).
RESULTS
The Effects of L-NAME and CIT on Morphological Values and BP
Litter sizes were not significantly altered by L-NAME exposure of the maternal rat (pups per litter: control ¼ 11.6 6 0.6; L-NAME ¼ 11 6 1) or by CIT therapy (CIT ¼ 11.2 6 0.7; L-NAMEþCIT ¼ 11 6 0.9). As shown in Table 1 , male pup mortality rates, body weight, kidney weight, and heart weight were not different among four groups. As shown in Figure 1 , the systolic BP of L-NAME group was significantly greater than that of the control from 8 to 12 wk of age during the development of hypertension. This increase in BP was prevented by CIT therapy. At 12 wk of age, systolic BP and mean arterial pressure of the L-NAME group were significantly increased compared with those of the control, which were prevented by maternal CIT therapy. We found no difference in plasma creatinine level among the four groups. Maternal L-NAME exposure offspring had significantly lower urinary TAIN ET AL. cGMP levels than the control. CIT therapy increased urinary cGMP levels in the L-NAMEþCIT group compared to the L-NAME group.
The Effects of L-NAME and CIT on the L-Arginine-ADMA-NO Pathway
We next investigated whether L-NAME exposure induces ADMA-NO imbalance while maternal CIT therapy prevents it. Our results showed that plasma levels of L-citrulline, Larginine, and SDMA were not different among the four groups (Table 2 ). Plasma ADMA level was higher in the L-NAME-CIT group compared to the other three groups. In the kidney, CIT therapy significantly decreased ADMA and SDMA concentrations in the L-NAMEþCIT group compared to the L-NAME group. Interestingly, the L-arginine-to-ADMA ratio was not altered in the plasma, while this ratio was higher in the L-NAMEþCIT group than in the control and L-NAME groups in the kidney.
To check why L-NAME causes ADMA-NO imbalance, we measured expression and activity of proteins involved in the Larginine-ADMA-NO pathway. We observed that renal cortical endothelial nitric oxide synthase (NOS3) and neuronal NOS (NOS1) protein expression was not significant among the four groups (Fig. 2, B and C) . Similarly, protein levels of arginase II, ASS, and ASL in the kidney were not different among the four groups. Next, we found no difference in the ADMAsynthesizing enzyme protein arginine methyltransferase-1 (PRMT1) protein levels in the kidney among the four groups (Fig. 3B) . Similarly, the abundance of DDAH1, the ADMAmetabolizing enzyme, was approximately the same among the four groups (Fig. 3C) . However, its isoenzyme DDAH2 protein level was higher in both the CIT and the L-NAMEþCIT group compared to the control (Fig. 3D) . As shown in Figure 3E , renal DDAH activity was higher in the L-NAMEþCIT and CIT groups than in the L-NAME group.
The Effects of L-NAME and CIT on RAS and Sodium Transporters
In order to investigate the mechanisms involved in programmed hypertension, we evaluated the renal mRNA expression of RAS components and sodium transporters. The Agtr1b and Mas1 mRNA expression was higher in the L-NAMEþCIT group than in the control group in the 12-wk-old offspring kidney (Fig. 4A) . As shown in Figure 4B , L-NAME exposure significantly increased mRNA expression of Slc9a3 in the kidney compared to the control. Renal expression Slc9a3 was lower in the CIT group than in the L-NAME group. However, renal expression of Slc12a1, Slc12a3, and Atp1a1 was comparable among the four groups. We further analyzed protein levels of angiotensin II type 2 receptor (AT2R), MAS, and type 3 sodium hydrogen exchanger (NHE3) in the kidney. We observed that AT2R and MAS protein abundance in the kidney was comparable among the four groups (Fig. 5, B and C). Maternal L-NAME exposure significantly increased renal NHE3 protein level, which was prevented by CIT therapy (Fig.  5D) .
DISCUSSION
This study provides insight into a novel mechanism by which maternal CIT therapy prevents the programmed hypertension in adult offspring induced by L-NAME treatment in pregnant rats. Our major findings can be summarized as follows: 1) NO inhibition by L-NAME during pregnancy induces hypertension in male offspring at 12 wk of age; 2) maternal CIT therapy prevents L-NAME-induced programmed hypertension, which was related to a decreased ADMA concentration and an increased L-arginine-to-ADMA ratio in the kidney and increased urinary cGMP levels; and 3) prenatal L-NAME exposure increased renal protein abundance of the FIG. 1. Effect of maternal L-NAME treatment and CIT supplementation on systolic blood pressure at different ages in male offspring. L-NAME ¼ mother rats received L-NAME. CIT ¼ mother rats received 0.25% Lcitrulline in drinking water during the whole period of pregnancy and lactation. L-NAMEþCIT ¼ mother rats received both L-NAME and Lcitrulline treatment. N ¼ 10/group. *P , 0.05 versus control; #P , 0.05 versus L-NAME.
CITRULLINE PREVENTS l-NAME-INDUCED HYPERTENSION sodium transporter NHE3, which CIT therapy prevented. 
FIG. 2. Representative Western blots (A)
show NOS3 (150 kDa), NOS1 (160 kDa), arginase II (40 kDa), ASS (50kDa), and ASL (50 kDa) at 3 mo of age in controls and in offspring from rats with maternal L-NAME treatment and/or supplemented with CIT. Relative abundance of renal cortical NOS3 (B), NOS1 (C), arginase II (D), ASS (E), and ASL (F) were quantified. N ¼ 6/group. L-NAME ¼ mother rats received L-NAME. CIT ¼ mother rats received 0.25% Lcitrulline in drinking water during the whole period of pregnancy and lactation. L-NAMEþCIT ¼ mother rats received both L-NAME and L-citrulline treatment.
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FIG. 3. Representative Western blots (A)
show PRMT1 (42 kDa) and DDAH1 (34 kDa) and DDAH2 (30 kDa) bands at 3 mo of age in controls and in offspring from rats with maternal L-NAME treatment and/or supplemented with CIT. Relative abundances of renal cortical PRMT1 (B), DDAH1 (C), DDAH2 (D), and renal DDAH activity (E) were quantified. N ¼ 6/group. L-NAME ¼ mother rats received L-NAME. CIT ¼ mother rats received 0.25% Lcitrulline in drinking water during the whole period of pregnancy and lactation. L-NAMEþCIT ¼ mother rats received both L-NAME and L-citrulline treatment. *P , 0.05 versus control; #P , 0.05 versus L-NAME.
FIG. 4.
Effect of maternal L-NAME treatment and CIT supplementation on gene expression of RAS components (A) and sodium transporters in the kidney (B). L-NAME ¼ mother rats received L-NAME. CIT ¼ mother rats received 0.25% L-citrulline in drinking water during the whole period of pregnancy and lactation. L-NAMEþCIT ¼ mother rats received both L-NAME and L-citrulline treatment. N ¼ 6/group. *P , 0.05 versus control; #P , 0.05 versus L-NAME.
CITRULLINE PREVENTS l-NAME-INDUCED HYPERTENSION that L-NAME-induced NO deficiency in pregnancy causes programmed hypertension and that restoration of NO by CIT supplementation is a potential approach to prevent this effect. A balanced L-arginine-ADMA-NO pathway to provide physiological levels of NO is essential for a successful outcome of pregnancy [1, 21] . Both L-NAME and ADMA have been reported to induce hypertension in adult rodents [9, 10, 22] . We chose L-NAME for NO inhibition in this study because L-NAME has been examined in pregnant rats and is not metabolized by DDAH. The role of NO inhibition in the development of programmed hypertension is undetermined, and to our knowledge, the present study is the first to determine the effect of CIT supplementation on restoration of NO to prevent programmed hypertension in an NO depletion model. Because CIT is taken up mainly by the kidney and metabolized into L-arginine, CIT supplementation is considered to increase L-arginine, thereby preventing NO deficiency [16] . We and others have shown that early CIT therapy can increase NO and reduce oxidative stress to prevent late onset of hypertension in spontaneously hypertensive rat and in other programming models [7, 14, 15, 17, 18] . Our findings support the idea that early restoration of a disturbed ROS/NO balance can prevent the development of programmed hypertension.
Our data demonstrated that L-NAME exposure had no effect on NOS isoenzymes and ADMA-synthesizing enzyme, while CIT significantly increased renal DDAH2 protein levels. We recently found that ROS induces ADMA accumulation by inhibiting DDAH activity [23] , which can be prevented by antioxidants [12, 24] . We observed that DDAH activity and the L-arginine-to-ADMA ratio were decreased in the kidney in L-NAME-exposed offspring. The L-arginine-to-ADMA ratio has been considered to reflect NO bioavailability in the kidney. Our recent report showed that maternal CIT therapy can restore renal NO production to prevent programmed hypertension in a prenatal dexamethasone model [17] . Despite the opposite levels of ADMA and L-arginine observed between serum and kidney, our findings suggest that CIT therapy restored inhibitory DDAH activity in the kidney to metabolize excessive ADMA from the plasma, increase the L-arginineto-ADMA ratio and NO production in the kidney, and prevent L-NAME-induced programmed hypertension.
Alterations of RAS and sodium transporters in the kidney have been reported to be critical mechanisms in fetal programming of hypertension [8] . Several RAS components, such as Ren, Ace, and Agtr1a, could be epigenetically regulated in a variety of programming models [8, 17] . We found no Mas receptor (MAS; 37k Da), and NHE3 (90 kDa) at 3 mo of age in controls and in offspring from rats with maternal L-NAME treatment and/or supplemented with CIT. Relative abundance of renal cortical AT2R (B), MAS (C), and NHE3 (D) were quantified. N ¼ 6/group. L-NAME ¼ mother rats received L-NAME. CIT ¼ mother rats received 0.25% L-citrulline in drinking water during the whole period of pregnancy and lactation. L-NAMEþCIT ¼ mother rats received both L-NAME and L-citrulline treatment. *P , 0.05 versus control; #P , 0.05 versus L-NAME.
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difference in mRNA expression of RAS components in the kidney between the L-NAME group and the control group. Nevertheless, CIT therapy increased renal mRNA expression of Agtr1b and Mas1. As another important axis of the RAS, ACE2 appears to adjust AT2R and angiotensin (1-7) receptor MAS in a way that opposes the development of hypertension [25] . Thus, another protective effect of maternal CIT therapy on programmed hypertension might be due to upregulation of Agtr1b and Mas1 to elicit vasodilatation. Nevertheless, we also found discrepancies in mRNA and protein levels as a result of programming at the transcriptional and posttranscriptional levels. Despite the increases in mRNA, the protein levels of AT2R and MAS were unaltered by CIT therapy. Thus, upregulation of mRNA by CIT therapy might be a compensatory response to its BP-lowering effect. In addition to RAS, alterations of sodium transporters favoring sodium retention are linked to the development of hypertension [8] . This concept is supported by our data showing that maternal CIT supplementation prevents L-NAME-induced increased NHE3 expression in the kidney. This finding is consistent with a previous study showing that renal NHE3 expression was increased in a prenatal dexamethasone exposure model [26] .
One limitation in this study is that we did not conduct a group with dietary supplementation with isonitrogenous Lalanine as the control. A second limitation is that we did not examine gender difference in response to L-NAME exposure in utero. Given that we detected BP in young adulthood and that cardiovascular events occurred at a later age in females than males, only male offspring were recruited in this study. Nonetheless, we acknowledge the importance of gender in developmental programming of hypertension, and this is worthy of further study in the future. Finally, it is noteworthy that there is a tendency for CIT lowering diastolic BP and mean arterial BP versus the control. Whether early CIT therapy alone elicits an adverse programming effect on normal persons in clinical practice awaits further evaluation.
In conclusion, maternal NO inhibition induced programmed hypertension, whereas CIT therapy prevented the increase of BP. Maternal CIT therapy prevented L-NAME-induced programmed hypertension, which was associated with a decreased ADMA concentration and an increased L-arginine-to-ADMA ratio in the kidney, increased urinary cGMP levels, and a decreased renal protein level of NHE3. Our results also indicate the importance of understanding basic knowledge about reproductive biology as well as redox balance to prevent programmed hypertension in pregnancy with NO deficiency. We expect the findings from this study to provide a strong scientific basis for supplementing CIT in pregnant women to improve fetal development and prevent programmed hypertension.
